Report Viewer
NINDS CDE Notice of Copyright
Multiple%20Sclerosis%20Severity%20Score%20(MSSS)
Multiple%20Sclerosis%20Severity%20Score%20(MSSS)
| Availability |
Please visit this website for more information about the instrument: https://www.ncbi.nlm.nih.gov/pubmed/15824338
|
| Classification |
Supplemental
|
| Short Description of Instrument |
Construct measured: Disease severity
Generic vs. disease specific: Disease-specific
Means of administration:
Intended respondent:
# of items: N/A
# of subscales and names of sub-scales: N/A
# of items per sub-scale: N/A
|
| Comments/Special Instructions |
Background: The Multiple Sclerosis Severity Score (MSSS) is a powerful method for comparing disease progression using single assessment data. The Global MSSS can be used as a reference table for future disability comparisons. While useful for comparing groups of patients, disease fluctuation precludes its use as a predictor of future disability in an individual. This scale was developed, based on a statistical approach combining Kurtzke's Expanded Disability Status Scale score (EDSS) with historical databases. It aims to provide a measure for disease severity in an individual patient on a cross–sectional basis.
|
| References |
Roxburgh RH, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005 Apr; 15;64(7):1144-1151.
Gray OM et al. The Multiple Sclerosis Severity Score (MSSS) re-examined: EDSS rank stability in the MSBase dataset increases 5 years after onset of multiple sclerosis Neurology Asia. 2008; 13: 217 - 219.
Document last updated July 2019
|
| Rationale/Justification |
Strengths/Weaknesses: The authors report that the MSSS can be used as a reference table for future disability comparisons of groups of patients, but that disease fluctuation precludes its use as a predictor of future disability in an individual (Roxburgh et al. 2005).
Psychometric Properties: The validity of the MSSS as a 5-year severity rank predictor in individual patients with MS in a clinical setting, has been supported, particularly from 5 year disease duration onwards (Gray et al 2008).
|